0.4 ML adalimumab-aaty 100 MG/ML Auto-Injector

RxCUI: 2639651
RxNorm name: 0.4 ML adalimumab-aaty 100 MG/ML Auto-Injector
Display name: 0.4 ML adalimumab-aaty 100 MG/ML Auto-Injector
Full name: 0.4 ML adalimumab-aaty 100 MG/ML Auto-Injector
Term type: SCD
Status: DailyMed mapping
Updated: 2026-06-04 23:38:58

Purple Book Biologic Products#

BLA, Proprietary name, Proper name table
BLA	Proprietary name	Proper name	License type	Status	Latest source
761219	Yuflyma	adalimumab-aaty	351(k) Interchangeable	Rx	2026-06-01

RxNav Current And Historical NDCs#

RxNav current and historical NDC rows page 1 of 1 · 0 matching rows.

No records found.

UNII Substances#

UNII substance links page 1 of 1 · 0 matching rows.

No records found.

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 2 matching rows.

Brand, Generic, Manufacturer table
Brand	Generic	Manufacturer	SPL set ID	Effective date	Available safety fields	Join
Yuflyma	ADALIMUMAB-AATY	CELLTRION USA, Inc.	526d626f-8c9f-496c-b838-00a73bb36383	2026-07-15	Boxed warning, Warnings, Adverse reactions	Exact identifier rxcui: 2639651
Adalimumab	ADALIMUMAB-AATY	CELLTRION USA, Inc.	c44365e9-d470-4e35-978d-8565a9e3471e	2026-07-08	Boxed warning, Warnings, Adverse reactions	Exact identifier rxcui: 2639651

DailyMed RxNorm Mappings#

Set ID, RxNorm string, TTY table
Set ID	RxNorm string	TTY	SPL version	Label	Effective
526d626f-8c9f-496c-b838-00a73bb36383	adalimumab-aaty 40 MG per 0.4 ML Auto-Injector	SY	13	These highlights do not include all the information needed to use YUFLYMA safely and effectively. See full prescribing information for YUFLYMA. YUFLYMA (adalimumab-aaty) injection, for subcutaneous use Initial U.S. Approval: 2023 YUFLYMA (adalimumab-aaty) is biosimilar Biosimilar means that the biological product is approved basetd on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful differences betwe	20251028
526d626f-8c9f-496c-b838-00a73bb36383	adalimumab-aaty 40 MG in 0.4 ML Auto-Injector	PSN	13	These highlights do not include all the information needed to use YUFLYMA safely and effectively. See full prescribing information for YUFLYMA. YUFLYMA (adalimumab-aaty) injection, for subcutaneous use Initial U.S. Approval: 2023 YUFLYMA (adalimumab-aaty) is biosimilar Biosimilar means that the biological product is approved basetd on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful differences betwe	20251028
526d626f-8c9f-496c-b838-00a73bb36383	0.4 ML adalimumab-aaty 100 MG/ML Auto-Injector	SCD	13	These highlights do not include all the information needed to use YUFLYMA safely and effectively. See full prescribing information for YUFLYMA. YUFLYMA (adalimumab-aaty) injection, for subcutaneous use Initial U.S. Approval: 2023 YUFLYMA (adalimumab-aaty) is biosimilar Biosimilar means that the biological product is approved basetd on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful differences betwe	20251028
c44365e9-d470-4e35-978d-8565a9e3471e	adalimumab-aaty 40 MG in 0.4 ML Auto-Injector	PSN	6	These highlights do not include all the information needed to use ADALIMUMAB-AATY safely and effectively. See full prescribing information for ADALIMUMAB-AATY. ADALIMUMAB-AATY injection, for subcutaneous use Initial U.S. Approval: 2023 This product is YUFLYMA (adalimumab-aaty). Adalimumab-aaty is biosimilar* to HUMIRA (adalimumab).	20251028
c44365e9-d470-4e35-978d-8565a9e3471e	adalimumab-aaty 40 MG per 0.4 ML Auto-Injector	SY	6	These highlights do not include all the information needed to use ADALIMUMAB-AATY safely and effectively. See full prescribing information for ADALIMUMAB-AATY. ADALIMUMAB-AATY injection, for subcutaneous use Initial U.S. Approval: 2023 This product is YUFLYMA (adalimumab-aaty). Adalimumab-aaty is biosimilar* to HUMIRA (adalimumab).	20251028
c44365e9-d470-4e35-978d-8565a9e3471e	0.4 ML adalimumab-aaty 100 MG/ML Auto-Injector	SCD	6	These highlights do not include all the information needed to use ADALIMUMAB-AATY safely and effectively. See full prescribing information for ADALIMUMAB-AATY. ADALIMUMAB-AATY injection, for subcutaneous use Initial U.S. Approval: 2023 This product is YUFLYMA (adalimumab-aaty). Adalimumab-aaty is biosimilar* to HUMIRA (adalimumab).	20251028